[A20-111] Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Benefit assessment according to §35a Social Code Book V
Last updated 04.06.2021
Project no.:
A20-111
Commission:
Commission awarded on 02.12.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with advanced (FIGO stages III and V) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status.
Patients without detectable tumour after primary surgery and patients without detectable tumour/with complete response following chemotherapy: indication of considerable added benefit.
Patients without detectable tumour after interval surgery and patients with partial response: indication of lesser benefit.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A19-56 | Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-57 | Olaparib (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-36 | Olaparib (ovarian, fallopian tube, peritoneal cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G15-05 | Olaparib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment) | Commission completed |
| A20-115 | Olaparib (adenocarcinoma of the pancreas) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-106 | Olaparib (prostate cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-55 | Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Addendum to Commission A20-111 | Commission completed |
Federal Joint Committee (G-BA)
2021.06.04 A G-BA decision was published.